Igenomix

What Igenomix does

Igenomix is a reproductive genetics testing company that provides laboratory-based diagnostic services to IVF clinics, fertility specialists, and patients across the reproductive journey. Founded in Valencia, Spain (legal entity registered 2009; firmographic founding year cited as 1996), the company operates a portfolio of proprietary genetic assays built on Next Generation Sequencing (NGS), 248-gene endometrial expression profiling, and cell-free DNA analysis. Its product suite includes ERA (Endometrial Receptivity Analysis), EMBRACE (non-invasive PGT-A using spent culture media), PGT-A, PGT-M, EMMA (endometrial microbiome), ALICE (chronic endometritis detection), EndomeTRIO, NACE (non-invasive prenatal test), CGT (carrier genetic test), POC (products of conception), SAT (sperm aneuploidy test), and IGX1 (CD133+ stem cell therapy with EMA Orphan Drug Designation).

The company monetizes through professional services fees for laboratory-based testing delivered to IVF clinics via a B2B enterprise sales model, with digital integration, customized clinical reports, genetic counseling, and e-learning platform access layered onto the core lab services. Distribution is anchored by 19-23 global laboratories enabling local sample processing and international parcel-based sample transport, with operations spanning 14 country sites including the US, Brazil, Canada, Mexico, Spain, Italy, UK, Turkey, Japan, Korea, Taiwan, India, UAE, and LATAM. The company reports 600+ professional employees, 460+ peer-reviewed scientific publications, and 4+ patents including the foundational ERA gene expression patent (PCT/ES2009/000386).

Following its 2021 acquisition by Vitrolife, Igenomix operates as part of Vitrolife Group, combining reproductive genetics testing with Vitrolife's IVF equipment portfolio. The company is led by Prof. Carlos Simón as Chief Scientific Officer and maintains active R&D including EU-funded programs (Marie Curie IAPP, EUREKA-EUROSTAR), pending patents on uterine leiomyoma diagnostics, and a non-invasive ERA liquid biopsy development program targeting embryo transfer personalization.

Name

Igenomix

Legal name

IGENOMIX S.L

Website

https://igenomix.com.tr

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Igenomix is a Valencia, Spain-based reproductive genetics testing company that provides proprietary laboratory assays (ERA, PGT-A, EMBRACE, NACE, EMMA, ALICE) to IVF clinics and fertility specialists globally through 19+ laboratories, operating as part of Vitrolife Group following its 2021 acquisition.

Ownership category

akta.pro rank

Product category

Reproductive Genetics Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• Reproductive genetics testing
• IVF genetic diagnostics
• Preimplantation genetic testing
• Endometrial receptivity analysis
• Non-invasive prenatal testing

Headquarters

HQ city

Valencia

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Testing Services: Laboratory-based genetic testing services for reproductive health, including ERA, PGT-A, NACE, and other reproductive genetics tests delivered to IVF clinics and fertility specialists

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Igenomix provides laboratory-based reproductive genetic testing services to IVF clinics and fertility specialists worldwide. Its portfolio spans preconception carrier screening (CGT), embryo testing (PGT-A, PGT-M, EMBRACE), endometrial health assessment (ERA, EMMA, ALICE, EndomeTRIO), non-invasive prenatal screening (NACE), and miscarriage analysis (POC, SAT), delivered through a global network of regional laboratories.

Product overview

Igenomix is a research-focused laboratory group specializing in reproductive genetics testing services for IVF clinics and fertility patients worldwide. The product portfolio centers on genetic testing solutions across the reproductive journey—from preconception carrier screening (CGT), through IVF embryo testing (PGT-A, PGT-M, EMBRACE), to endometrial assessment (ERA, EMMA, ALICE, EndomeTRIO), prenatal testing (NACE), and miscarriage analysis (POC). Services are delivered through a network of 19-23 laboratories globally, with a research arm developing new diagnostic technologies. The company operates as part of Vitrolife Group following acquisition in 2021.

Differentiator

Problem solved

Functional benefit

Brands

• ERA: Endometrial Receptivity Analysis - determines the optimal day for embryo transfer to prevent implantation failure
• EMMA
• ALICE
• EndomeTRIO
• EMBRACE
• PGT-A
• PGT-M
• CGT
• POC
• SAT

Products and services

• ERA (Endometrial Receptivity Analysis)

Quantifiable outcome

• 73% pregnancy rate improvement with personalized ERA-based embryo transfer
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Four partnerships are on record, tiered core, strategic and minor.

• Vitrolife GroupcoreStrategic or Co-development Partner · 1 January 2021In 2021, Vitrolife acquired Igenomix. Together they form a global leader in reproductive health. Igenomix's reproductive genetics testing portfolio is combined with Vitrolife's best-in-class IVF equipment portfolio to support clinics and patients throughout the fertility journey.
• AsphalionstrategicImplementation/ SI/ Consulting PartnerRegulatory affairs partnership for EMA Orphan Drug Designation application process. Asphalion provided support for justification of Asherman's syndrome as a rare disease, medical plausibility, and attended face-to-face meeting at EMA. Team included Núria Coderch, Christopher Mann, Joel Montané, Jesús Delgado, and Mireia Lorenzo.
• IVI (Instituto Valenciano de Infertilidad)strategicStrategic or Co-development PartnerCo-organizer of 7th International IVI Congress in Bilbao, Spain. Igenomix participated with booth presence and expert speakers including Carlos Simón, Carlos Rubio, Antonio Díez-Juan, and Irina Moreno presenting on genetics topics.
• EXPERMED CongressminorStrategic or Co-development PartnerIgenomix co-organizes the II International Expermed Congress in Kyrenia, Cyprus. Booth #20 for genetic testing services showcase.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Natera: U.S.-based genetic testing company offering PGT-A via its Empower test, NIPT (Vistara), and carrier screening — a direct head-to-head competitor in reproductive genetics serving IVF clinics and patients.
• Invitae (now part of Labcorp): Genetic testing company (acquired by Labcorp) offering comprehensive hereditary and reproductive carrier screening, directly overlapping Igenomix's CGT, PGT-M, and embryo-related testing services.
• Myriad Genetics: Established genetic diagnostics company whose Foresight carrier screen and broader reproductive health portfolio compete with Igenomix's CGT and adjacent prenatal/preconception testing.
• Genomic Prediction: Specialized reproductive genetics laboratory offering PGT-A and PGT-P (polygenic) testing, competing with Igenomix specifically in advanced embryo screening for IVF clinics.
• Sema4 (part of GeneDx): Genomics company with a reproductive health franchise including PGT, NIPT, and carrier screening, providing direct competition in the same IVF-clinic channel.
• CooperGenomics (CooperSurgical): Reproductive genetics laboratory within CooperSurgical providing PGT-A, PGT-M, and carrier screening services to IVF clinics globally, overlapping directly with Igenomix's core test menu.

Broad incumbents

• Quest Diagnostics: Diversified U.S. diagnostics giant with genetic and women's health testing capabilities that overlap with Igenomix in NIPT and carrier screening markets.
• Labcorp: Large clinical diagnostics platform (now including Invitae) offering genetic and reproductive testing as part of a broader lab services portfolio — competes with Igenomix while serving a much wider testing menu.
• BioReference Laboratories (OPKO Health): Specialty diagnostics laboratory (within OPKO Health) offering reproductive and genetic testing for fertility clinics and physicians, providing partial overlap to Igenomix's clinical-channel service model.

Emerging players

• Fulgent Genetics: Genetic testing company expanding into reproductive and carrier screening with a flexible, tech-forward platform — an emerging, less specialized competitor in select geographies where Igenomix operates.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Igenomix